First FDA-Approved Drug Offers New Hope for Patients With Rare Brain Disease
The FDA approved Zanvastro, containing zilganersen, as the first treatment specifically developed for Alexander disease, a rare genetic disorder affecting the brain and nervous system. Administered by spinal injection every three months, the therapy targets underlying disease mechanisms and was associated with improved walking speed in clinical research.
Ionis Pharmaceuticals plans to launch the treatment in the United States within weeks at a reported price of $285,000 per dose. The approval expands options for patients with limited treatments while highlighting the financial challenges of developing and accessing rare-disease medicines.
The U.S. Food and Drug Administration has approved the first treatment specifically designed for Alexander disease, a rare and serious neurodegenerative disorder. The decision marks an important medical milestone for patients and families who have historically faced very limited treatment options. The approval gives the rare-disease community access to a therapy developed specifically to address the biological processes associated with the condition.
Alexander disease is a genetic disorder that damages cells in the brain and nervous system. Depending on the form and stage of the disease, patients can experience difficulties with movement, speech, coordination and swallowing. Because the disorder affects a relatively small number of people, research and drug development have faced significant challenges compared with more common neurological conditions.
The newly approved treatment, Zanvastro, was developed by Ionis Pharmaceuticals and contains the active ingredient zilganersen. The therapy is administered by a healthcare professional through an injection into the spinal canal every three months. Its development reflects growing efforts to use advanced molecular approaches to target the underlying mechanisms of rare neurological diseases rather than focusing only on managing symptoms.
Clinical research provided evidence supporting the treatment’s effectiveness. In the study, patients receiving the 50-milligram dose showed a statistically significant improvement in walking speed during the treatment period. Walking ability is an important measure for people affected by progressive neurological disorders because declining mobility can significantly influence independence and everyday activities.
The approval also highlights the financial challenges surrounding rare-disease medicines. Ionis has announced a price of $285,000 per dose and expects the treatment to become available in the United States within weeks. The company expects peak annual sales to exceed $100 million while continuing research into the therapy. The high price reflects the broader debate over how innovative treatments can be developed while remaining accessible to patients who need them.
For families affected by Alexander disease, the approval represents a major change after years in which treatment choices were extremely limited. It also demonstrates how investment in rare-disease research can produce therapies for conditions affecting relatively small patient populations. As researchers continue studying neurological disorders, the development could encourage further work aimed at transforming scientific discoveries into practical treatments for patients with complex diseases.
